Sugi Predict

Sugi Predict / Compounds / SCHEMBL1712936

SCHEMBL1712936

SCHEMBL1712936

O=C(O)[C@@H](O)c1cccc(Cl)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.59
▸ MAPK1 P28482 1/20 0.59
▸ MEN1 O00255 2/20 0.53
▸ KMT2A Q03164 2/20 0.53
▸ ACP3 P15309 1/20 0.51
▸ KEAP1 Q14145 1/20 0.46
▸ NFE2L2 Q16236 1/20 0.46
▸ GLS O94925 1/20 0.45
▸ PARP1 P09874 1/20 0.42
▸ SRC P12931 1/20 0.42
▸ BLM P54132 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ ADRB1 P08588 1/20 0.42
▸ ADRB3 P13945 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ HPGD P15428 1/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ HTT P42858 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30147772 1.00 LMNA (0.59) LMNAMAPK1MEN1KMT2AACP3
SCHEMBL606570 1.00 LMNA (0.59) LMNAMAPK1MEN1KMT2AACP3
SCHEMBL606571 1.00 LMNA (0.59) LMNAMAPK1MEN1KMT2AACP3
SCHEMBL23972979 0.89 LMNA (0.52) LMNAMAPK1MEN1KMT2AACP3
SCHEMBL8866869 0.87 LMNA (0.50) LMNAMAPK1MEN1KMT2AACP3
SCHEMBL8868101 0.87 LMNA (0.50) LMNAMAPK1MEN1KMT2AACP3
SCHEMBL8866876 0.87 LMNA (0.50) LMNAMAPK1MEN1KMT2AACP3
SCHEMBL8866872 0.87 LMNA (0.50) LMNAMAPK1MEN1KMT2AACP3
SCHEMBL276569 0.85 LMNA (0.73) LMNAMAPK1KMT2ASRCBLM
SCHEMBL5064611 0.82 PARP1 (0.50) MEN1KMT2AACP3GLSPARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110124909-A1 NOVEL PROCESS GENERICS [UK] LIMITED (GB) 2011-05-26 — — US claimed
EP-2262761-A1 NOVEL PROCESS Generics [UK] Limited (GB) 2010-12-22 — — EP claimed
WO-2009122215-A1 NOVEL PROCESS GENERICS [UK] LIMITED (GB) 2009-10-08 — — WO claimed
US-20070270487-A1 Novel process and intermediates 085 ASTRAZENECA AB (SE) 2007-11-22 — — US claimed
US-10857517-B2 Porous chiral materials and uses thereof NANKAI UNIVERSITY (CN) 2020-12-08 — — US disclosed
EP-3196185-B1 ASYMMETRICAL HYDROGENATION REACTION OF KETONIC ACID COMPOUND ZHEJIANG JIUZHOU PHARMA SCIENCE & TECH CO LTD (CN) 2019-06-12 — — EP disclosed
CN-109689667-A Porous chiral material and use thereof 南开大学 2019-04-26 — — CN disclosed
US-20170260119-A1 Asymmetrical hydrogenation reaction of ketonic acid compound ZHEJIANG JIUZHOU PHARMA SCIENCE&TECHNOLOGY CO LTD (CN) 2017-09-14 — — US disclosed
US-20170260119-A1 Asymmetrical hydrogenation reaction of ketonic acid compound ZHEJIANG JIUZHOU PHARMA SCIENCE&TECHNOLOGY CO LTD (CN) 2017-09-14 — — US disclosed
EP-3196185-A1 ASYMMETRICAL HYDROGENATION REACTION OF KETONIC ACID COMPOUND Zhejiang Jiuzhou Pharma Science & Technology Co., Ltd. (CN) 2017-07-26 — — EP disclosed
US-9315792-B2 Nitrilases, nucleic acids encoding them and methods for making and using them BASF ENZYMES LLC (US) 2016-04-19 — — US disclosed
US-20160097063-A1 Production Of Enantiopure alpha-Hydroxy Carboxylic Acids From Alkenes By Cascade Biocatalysis NATIONAL UNIVERSITY OF SINGAPORE (SG) 2016-04-07 — — US disclosed
EP-0543662-A2 Aromatic amino-alcohol derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic uses Sankyo Company Limited (JP) 1993-05-26 — — EP disclosed
US-5198586-A Process for the preparation of phenylethanolaminotetralins SANOFI (FR) 1993-03-30 — — US disclosed
US-5041606-A Process for the O-alkylation of N-(hydroxy)aralkylphenylethanolamines SANOFI 1991-08-20 — — US disclosed
US-4927955-A Process for the O-alkylation of N-(hydroxy)aralkylphenylethanolamines SANOFI (FR) 1990-05-22 — — US disclosed
US-4297489-A CEPHALOSPORINS BRISTOL-MYERS COMPANY (US) 1981-10-27 — — US disclosed
US-4172196-A CEPHALOSPORINS BRISTOL-MYERS COMPANY (US) 1979-10-23 — — US disclosed
US-4112228-A BACTERICIDES BRISTOL-MYERS COMPANY (US) 1978-09-05 — — US disclosed
US-3985738-A ANTIBACTERIAL AGENTS BRISTOL-MYERS COMPANY (US) 1976-10-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070270487-A1 Novel process and intermediates 085 CYP3A5, AGPAT5, CYP4F8 LMNA 3669/4885MAPK1 1719/4885MEN1 3842/4885
US-20170260119-A1 Asymmetrical hydrogenation reaction of ketonic acid compound KHK, PKLR, BCKDK LMNA 3213/4885MAPK1 1240/4885MEN1 2149/4885
US-20110124909-A1 NOVEL PROCESS GABRE, GABRB2, GABRB1 LMNA 3715/4885MAPK1 3278/4885MEN1 4039/4885
US-10857517-B2 Porous chiral materials and uses thereof ANXA7, XDH, OPRM1 LMNA 219/4885MAPK1 1200/4885MEN1 412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.